Advertisement
Advertisement
ROIV
Roivant Sciences Ltd. Common Shares
28.22
USDSponsored
-0.26
-0.90%
Apr 10, 15:59 UTC -4
Closed
After-Market
28.25
+0.03
+0.09%
ROIV Earnings Reports
Positive Surprise Ratio
ROIV beat 9 of 18 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Roivant Sciences Ltd. Common Shares earnings per share and revenue
On Feb 06, 2026, ROIV reported earnings of -0.38 USD per share (EPS) for Q3 26, missing the estimate of -0.32 USD, resulting in a -17.28% surprise. Revenue reached 2.00 million, compared to an expected 6.60 million, with a -69.72% difference. The market reacted with a +22.14% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Roivant Sciences Ltd. Common Shares's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Roivant Sciences Ltd. Common Shares reported EPS of -$0.38, missing estimates by -17.28%, and revenue of $2.00M, -69.72% below expectations.
How did the market react to Roivant Sciences Ltd. Common Shares's Q3 2026 earnings?
The stock price moved up 22.14%, changed from $21.14 before the earnings release to $25.82 the day after.
When is Roivant Sciences Ltd. Common Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Roivant Sciences Ltd. Common Shares's next earnings report?
Based on --
analysts, Roivant Sciences Ltd. Common Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement